{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High-dose+aflibercept&page=2", "query": { "intervention": "High-dose aflibercept", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 25, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High-dose+aflibercept&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=High-dose+aflibercept&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T17:06:21.117Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06662994", "title": "High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetic Macular Edema (DME)" ], "interventions": [ { "name": "Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Retina Consultants of Orange County", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 15, "start_date": "2025-07-07", "completion_date": "2027-08-15", "has_results": false, "last_update_posted_date": "2025-07-10", "last_synced_at": "2026-10-19T17:06:21.117Z", "location_count": 1, "location_summary": "Fullerton, California", "locations": [ { "city": "Fullerton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06662994" }, { "nct_id": "NCT06047379", "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diffuse Astrocytoma, IDH-Mutant", "Glioblastoma, IDH-wildtype", "Brain Metastases, Adult", "Cervical Cancer", "Colorectal Cancer", "Esophageal Cancer", "Esophageal Squamous Cell Carcinoma", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Head and Neck Squamous Cell Carcinoma", "Melanoma", "Merkel Cell Carcinoma", "Microsatellite Instability-High Solid Malignant Tumor", "Mismatch Repair Deficient Solid Malignant Tumor", "Microsatellite Instability-High Colorectal Cancer", "Mismatch Repair Deficient Colorectal Cancer", "Non-small Cell Lung Cancer", "Renal Cell Carcinoma", "Small Cell Lung Cancer", "Squamous Cell Carcinoma", "Urothelial Carcinoma" ], "interventions": [ { "name": "NEO212 Oral Capsule", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "FOLFIRI Protocol", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neonc Technologies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 134, "start_date": "2023-11-01", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-19T17:06:21.117Z", "location_count": 8, "location_summary": "Beverly Hills, California • Glendale, California • Los Angeles, California + 5 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Boynton Beach", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06047379" }, { "nct_id": "NCT04126317", "title": "Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neovascular (Wet) Age-Related Macular Degeneration" ], "interventions": [ { "name": "aflibercept", "type": "DRUG" }, { "name": "High-dose aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 106, "start_date": "2019-11-04", "completion_date": "2021-11-30", "has_results": true, "last_update_posted_date": "2023-08-14", "last_synced_at": "2026-10-19T17:06:21.117Z", "location_count": 45, "location_summary": "Phoenix, Arizona • Sun City, Arizona • Encino, California + 42 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Sun City", "state": "Arizona" }, { "city": "Encino", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Mountain View", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04126317" }, { "nct_id": "NCT07705555", "title": "A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetic Retinopathy", "Macular Edema" ], "interventions": [ { "name": "MK-8748", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 960, "start_date": "2026-08-27", "completion_date": "2029-10-31", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-19T17:06:21.117Z", "location_count": 21, "location_summary": "Glendale, California • Sacramento, California • Denver, Colorado + 18 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Manchester", "state": "Connecticut" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07705555" }, { "nct_id": "NCT07440225", "title": "A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Macular Degeneration", "Age-Related Macular Degeneration", "Choroidal Neovascularization", "Wet Macular Degeneration" ], "interventions": [ { "name": "Tiespectus", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EyeBiotech Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 960, "start_date": "2026-03-27", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-19T17:06:21.117Z", "location_count": 67, "location_summary": "Scottsdale, Arizona • Fayetteville, Arkansas • Springdale, Arkansas + 59 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Glendale", "state": "California" }, { "city": "Modesto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07440225" }, { "nct_id": "NCT06495918", "title": "Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neovascular Age-related Macular Degeneration" ], "interventions": [ { "name": "OTX-TKI", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ocular Therapeutix, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": null, "sex": "ALL", "summary": "50 Years and older" }, "enrollment_count": 825, "start_date": "2024-11-27", "completion_date": "2027-01-08", "has_results": false, "last_update_posted_date": "2025-06-17", "last_synced_at": "2026-10-19T17:06:21.117Z", "location_count": 84, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 73 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06495918" }, { "nct_id": "NCT06550011", "title": "Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neovascular (Wet) AMD" ], "interventions": [ { "name": "ABI-110 Low Dose", "type": "DRUG" }, { "name": "ABI-110 Medium Dose", "type": "DRUG" }, { "name": "ABI-110 High Dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Avirmax Biopharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "50 Years to 89 Years" }, "enrollment_count": 18, "start_date": "2024-08-07", "completion_date": "2031-01-16", "has_results": false, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-10-19T17:06:21.117Z", "location_count": 4, "location_summary": "Bakersfield, California • Walnut Creek, California • San Antonio, Texas + 1 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "San Antonio", "state": "Texas" }, { "city": "The Woodlands", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06550011" }, { "nct_id": "NCT02192541", "title": "Ganetespib and Ziv-Aflibercept in Refractory Gastrointestinal Carcinomas, Non-Squamous Non-Small Cell Lung Carcinomas, Urothelial Carcinomas, and Sarcomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "Ziv-Aflibercept", "type": "DRUG" }, { "name": "Ganetespib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 5, "start_date": "2014-12-02", "completion_date": "2016-02-25", "has_results": true, "last_update_posted_date": "2018-03-29", "last_synced_at": "2026-10-19T17:06:21.117Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02192541" }, { "nct_id": "NCT05296447", "title": "Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Retinopathy, DR" ], "interventions": [ { "name": "Standard of Care", "type": "DRUG" }, { "name": "Aflibercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 100, "start_date": "2022-04-04", "completion_date": "2031-06", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-10-19T17:06:21.117Z", "location_count": 20, "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Mountain View", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05296447" }, { "nct_id": "NCT06116916", "title": "Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Macular Edema (DME)" ], "interventions": [ { "name": "KHK4951", "type": "DRUG" }, { "name": "Aflibercept Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyowa Kirin Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 185, "start_date": "2024-01-09", "completion_date": "2026-11-30", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-19T17:06:21.117Z", "location_count": 40, "location_summary": "Mesa, Arizona • Tucson, Arizona • Arcadia, California + 36 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Arcadia", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Encino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06116916" } ] }